• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

病例报告:一名伴有MYC和BCL2重排的TdT阳性高级别B细胞淋巴瘤患者在同时治疗滤泡性淋巴瘤和弥漫性大B细胞淋巴瘤后的突变演变。

Case report: Mutation evolution in a patient with TdT positive high grade B cell lymphoma with MYC and BCL2 rearrangements following the treatment of concurrent follicular lymphoma and diffuse large B-cell lymphoma.

作者信息

Zhang Fen, Chen Yu, Cui Qian, Ge Yan, Liu Yanhui

机构信息

Department of Pathology, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, No. 106, 2nd Zhongshan Road, Guangzhou, 510080, China.

出版信息

Discov Oncol. 2024 Apr 25;15(1):129. doi: 10.1007/s12672-024-00991-5.

DOI:10.1007/s12672-024-00991-5
PMID:38662249
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11045710/
Abstract

BACKGROUND

Concurrent follicular lymphoma (FL) and diffuse large B-cell lymphoma (DLBCL)was reported in some studies, while the diagnosis of TdT (terminal deoxynucleotydil transferase) positive high grade B cell lymphoma (HGBL) with MYC and BCL2 rearrangements ("double hit") transformed from FL/DLBCL has been rarely reported. Herein, we described the clinical features and mutation profiles of a case diagnosed with TdT positive "double hit" HGBL following the treatment of FL/DLBCL.

CASE PRESENTATION

This is a 43-year-old Chinese man who was diagnosed with low grade FL (account for 80%) combined with DLBCL (20%) at a stage of IVB. The patient presented with BCL2/IGH translocation without MYC rearrangement, as well as the expressions of CD20, CD19, CD10 and BCL2 at the initial diagnosis of FL/DLBCL. MYC rearrangement and TdT expression occurred after the treatment. The targeted sequencing revealed mutations in KMT2D, FOXO1, CREBBP, ATM, STAT6, BCL7A, DDX3X, MUC4, FGFR3, ARID5B, DDX11 and PRKCSH genes were the co-mutations shared by the FL/DLBCL and TdT positive "double hit" HGBL, while CCND3, BIRC6, ROBO1 and CHEK2 mutations specifically occurred after the treatment. The overall survival time was 37.8 and 17.8 months after the initial diagnosis of FL/DLBCL and TdT positive "double hit" HGBL, respectively.

CONCLUSION

This study reports a rare case of TdT positive "double hit" HGBL following the treatment of concurrent FL/DLBCL and highlights the mutation characteristics. Collectively, this study will help enrich the knowledge of TdT positive "double hit" HGBL transformed from FL/DLBCL.

摘要

背景

一些研究报道了滤泡性淋巴瘤(FL)与弥漫性大B细胞淋巴瘤(DLBCL)并存的情况,而由FL/DLBCL转化而来的伴有MYC和BCL2重排(“双打击”)的末端脱氧核苷酸转移酶(TdT)阳性高级别B细胞淋巴瘤(HGBL)的诊断鲜有报道。在此,我们描述了1例经FL/DLBCL治疗后诊断为TdT阳性“双打击”HGBL的临床特征和突变谱。

病例介绍

这是一名43岁的中国男性,在IVB期被诊断为低级别FL(占80%)合并DLBCL(20%)。患者在FL/DLBCL初诊时表现为BCL2/IGH易位但无MYC重排,以及CD20、CD19、CD10和BCL2的表达。治疗后出现MYC重排和TdT表达。靶向测序显示,KMT2D、FOXO1、CREBBP、ATM、STAT6、BCL7A、DDX3X、MUC4、FGFR3、ARID5B、DDX11和PRKCSH基因的突变是FL/DLBCL和TdT阳性“双打击”HGBL共有的共同突变,而CCND3、BIRC6、ROBO1和CHEK2突变则在治疗后特异性出现。FL/DLBCL和TdT阳性“双打击”HGBL初诊后的总生存时间分别为37.8个月和17.8个月。

结论

本研究报告了1例罕见的经FL/DLBCL治疗后TdT阳性“双打击”HGBL病例,并突出了其突变特征。总体而言,本研究将有助于丰富对由FL/DLBCL转化而来的TdT阳性“双打击”HGBL的认识。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/adc2/11045710/a3fb73cdf92f/12672_2024_991_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/adc2/11045710/02031777d40a/12672_2024_991_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/adc2/11045710/1b40a93d9d86/12672_2024_991_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/adc2/11045710/33d2b4c6ecb4/12672_2024_991_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/adc2/11045710/a3fb73cdf92f/12672_2024_991_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/adc2/11045710/02031777d40a/12672_2024_991_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/adc2/11045710/1b40a93d9d86/12672_2024_991_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/adc2/11045710/33d2b4c6ecb4/12672_2024_991_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/adc2/11045710/a3fb73cdf92f/12672_2024_991_Fig4_HTML.jpg

相似文献

1
Case report: Mutation evolution in a patient with TdT positive high grade B cell lymphoma with MYC and BCL2 rearrangements following the treatment of concurrent follicular lymphoma and diffuse large B-cell lymphoma.病例报告:一名伴有MYC和BCL2重排的TdT阳性高级别B细胞淋巴瘤患者在同时治疗滤泡性淋巴瘤和弥漫性大B细胞淋巴瘤后的突变演变。
Discov Oncol. 2024 Apr 25;15(1):129. doi: 10.1007/s12672-024-00991-5.
2
Transformation of Follicular Lymphoma to a High-Grade B-Cell Lymphoma With MYC and BCL2 Translocations and Overlapping Features of Burkitt Lymphoma and Acute Lymphoblastic Leukemia: A Case Report and Literature Review.滤泡性淋巴瘤转化为伴有MYC和BCL2易位的高级别B细胞淋巴瘤以及伯基特淋巴瘤和急性淋巴细胞白血病的重叠特征:一例报告及文献综述
Clin Med Insights Blood Disord. 2017 Feb 28;10:1179545X17692544. doi: 10.1177/1179545X17692544. eCollection 2017.
3
Double-Hit Gene Expression Signature Defines a Distinct Subgroup of Germinal Center B-Cell-Like Diffuse Large B-Cell Lymphoma.双打击基因表达特征定义了生发中心 B 细胞样弥漫性大 B 细胞淋巴瘤的一个独特亚群。
J Clin Oncol. 2019 Jan 20;37(3):190-201. doi: 10.1200/JCO.18.01583. Epub 2018 Dec 3.
4
[Genetic evolution of in situ follicular neoplasia to t(14;18)-positive aggressive B-cell lymphoma].[原位滤泡性肿瘤向t(14;18)阳性侵袭性B细胞淋巴瘤的基因进化]
Pathologe. 2021 Dec;42(Suppl 2):122-128. doi: 10.1007/s00292-021-01011-x. Epub 2021 Oct 20.
5
Follicular lymphoma and diffuse large B-cell lymphoma with BCL2 and IRF4 rearrangements in adult patients.成人滤泡性淋巴瘤和弥漫性大 B 细胞淋巴瘤伴 BCL2 和 IRF4 重排。
Hum Pathol. 2023 Nov;141:22-29. doi: 10.1016/j.humpath.2023.08.008. Epub 2023 Aug 25.
6
Mutational landscape of high-grade B-cell lymphoma with , and/or rearrangements characterized by whole-exome sequencing.通过全外显子组测序对具有 和/或 重排的高级别 B 细胞淋巴瘤的突变景观进行分析。
Haematologica. 2022 Aug 1;107(8):1850-1863. doi: 10.3324/haematol.2021.279631.
7
De novo acute lymphoblastic leukemia-like disease of high grade B-cell lymphoma with and and/or rearrangements: a case report and literature review.伴有 MYC、BCL2 和/或 BCL6 重排的高级别 B 细胞淋巴瘤的新发急性淋巴细胞白血病样疾病:一例报告及文献综述
BMC Clin Pathol. 2017 Nov 9;17:21. doi: 10.1186/s12907-017-0060-1. eCollection 2017.
8
[The role of translocations involving c-MYC/8q24, BCL2/18q21 and/or BCL6/3q27 genes in patients with follicular lymphoma. Retrospective analysis of single - centre data].[涉及c-MYC/8q24、BCL2/18q21和/或BCL6/3q27基因的易位在滤泡性淋巴瘤患者中的作用。单中心数据的回顾性分析]
Ter Arkh. 2019 Jul 15;91(7):52-62. doi: 10.26442/00403660.2019.07.000070.
9
Transformation of t(14;18)-negative follicular lymphoma to plasmablastic lymphoma: a case report with analysis of genetic evolution.t(14;18)阴性滤泡性淋巴瘤向浆母细胞淋巴瘤的转化:一例病例报告并分析遗传进化。
Diagn Pathol. 2024 Jun 22;19(1):86. doi: 10.1186/s13000-024-01512-2.
10
Clinicopathological and genomic analysis of double-hit follicular lymphoma: comparison with high-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements.双打击滤泡淋巴瘤的临床病理和基因组分析:与伴有 MYC 和 BCL2 及/或 BCL6 重排的高级别 B 细胞淋巴瘤的比较。
Mod Pathol. 2018 Feb;31(2):313-326. doi: 10.1038/modpathol.2017.134. Epub 2017 Oct 6.

本文引用的文献

1
Simplified algorithm for genetic subtyping in diffuse large B-cell lymphoma.弥漫性大 B 细胞淋巴瘤的遗传亚型简化算法。
Signal Transduct Target Ther. 2023 Apr 10;8(1):145. doi: 10.1038/s41392-023-01358-y.
2
Genomic landscape of follicular lymphoma across a wide spectrum of clinical behaviors.弥漫大 B 细胞淋巴瘤的基因组景观具有广泛的临床行为谱。
Hematol Oncol. 2023 Oct;41(4):631-643. doi: 10.1002/hon.3132. Epub 2023 Mar 30.
3
Chidamide and sintilimab combination in diffuse large B-cell lymphoma progressing after chimeric antigen receptor T therapy.
西达本胺与信迪利单抗联合治疗嵌合抗原受体T细胞疗法后进展的弥漫性大B细胞淋巴瘤
World J Clin Cases. 2022 Jul 6;10(19):6555-6562. doi: 10.12998/wjcc.v10.i19.6555.
4
[Clinical features and outcomes of newly diagnosed follicular lymphoma concurrent with diffuse large B-cell lymphoma component].[新诊断的伴有弥漫性大B细胞淋巴瘤成分的滤泡性淋巴瘤的临床特征及预后]
Zhonghua Xue Ye Xue Za Zhi. 2022 Jun 14;43(6):456-462. doi: 10.3760/cma.j.issn.0253-2727.2022.06.003.
5
Screening of Adverse Prognostic Factors and Construction of Prognostic Index in Previously Untreated Concurrent Follicular Lymphoma and Diffuse Large B-Cell Lymphoma.未经治疗的滤泡性淋巴瘤和弥漫性大 B 细胞淋巴瘤患者不良预后因素的筛选及预后指数的构建。
Biomed Res Int. 2022 May 24;2022:4379556. doi: 10.1155/2022/4379556. eCollection 2022.
6
Toxicity of Immune-Checkpoint Inhibitors in Hematological Malignancies.免疫检查点抑制剂在血液系统恶性肿瘤中的毒性
Front Pharmacol. 2021 Aug 13;12:733890. doi: 10.3389/fphar.2021.733890. eCollection 2021.
7
Mutational Landscape of TdT+ Large B-cell Lymphomas Supports Their Distinction From B-lymphoblastic Neoplasms: A Multiparameter Study of a Rare and Aggressive Entity.TdT+ 大 B 细胞淋巴瘤的突变景观支持其与 B 淋巴母细胞肿瘤的区分:一种罕见且侵袭性实体的多参数研究。
Am J Surg Pathol. 2022 Jan 1;46(1):71-82. doi: 10.1097/PAS.0000000000001750.
8
Durable Response to Sintilimab and Chidamide in a Patient With Pegaspargase- and Immunotherapy-Resistant NK/T-Cell Lymphoma: Case Report and Literature Review.培门冬酶和免疫治疗耐药的NK/T细胞淋巴瘤患者对信迪利单抗和西达本胺的持久反应:病例报告及文献综述
Front Oncol. 2020 Dec 11;10:608304. doi: 10.3389/fonc.2020.608304. eCollection 2020.
9
Cyclin D3 drives inertial cell cycling in dark zone germinal center B cells.周期蛋白 D3 驱动暗区生发中心 B 细胞的惯性细胞周期。
J Exp Med. 2021 Apr 5;218(4). doi: 10.1084/jem.20201699.
10
Mutational landscape of gray zone lymphoma.灰区淋巴瘤的突变景观。
Blood. 2021 Apr 1;137(13):1765-1776. doi: 10.1182/blood.2020007507.